Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
22 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Can-Fite BioPharma Ltd.’s names, not what it holds today.
Patents granted
22
22 utility, 1976 to Dec 31, 2025
Granted in 2025
1
in the last year the record reads
Applications published
28
2 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'10'11'12'13'14'15'16'17'18'19'20'21'22'23'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
CAN-FITE BIOPHARMA LTD. its own name
IL, as the owner printed on each patent. 1 more under the same name are not counted (printed in US)
24 publishedCAN-FITE BIOPHARMA LTD. its own name
named as the applicant on its applications, in IL
4 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Feb 4, 2025 | 12,213,990 | A3 adenosine receptor ligand for use for achieving a fat loss effect | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Apr 5, 2022 | 11,291,681 | Method for treating fibrotic liver tissue using Cl-IB-MECA | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Sep 22, 2020 | 10,780,106 | Method for treating NASH accompanied by fibrosis using Cl-IB-MECA | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Apr 23, 2019 | 10,265,337 | Use of A3 adenosine receptor agonist in osteoarthritis treatment | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Jan 24, 2017 | 9,549,943 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Jul 12, 2016 | 9,387,220 | Method for inducing hepatocyte proliferation and uses thereof | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Aug 11, 2015 | 9,102,698 | Process for the synthesis of IB-MECA | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Mar 24, 2015 | 8,987,228 | Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Sep 30, 2014 | 8,846,635 | Method for inducing hepatocyte proliferation and uses thereof | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Oct 15, 2013 | 8,557,790 | A3 adenoside receptor agonists for the reduction of intraocular pressure | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Dec 25, 2025 | 2025/0387424 | PHARMACEUTICAL COMPOSITION COMPRISING A3 ADENOSINE RECEPTOR AGONIST FOR TREATMENT OF PSORIASIS | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Dec 4, 2025 | 2025/0368676 | PROCESS FOR PREPARING NAMODENOSON | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Jun 29, 2023 | 2023/0201240 | TREATMENT OF ADVANCED METASTATIC CANCER | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Feb 16, 2023 | 2023/0049415 | CANNABINOIDS FOR USE IN TREATMENT | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Mar 17, 2022 | 2022/0079968 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. · patent 12,213,990 granted from it |
| Mar 11, 2021 | 2021/0069227 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. |
| Dec 10, 2020 | 2020/0384009 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. · patent 11,291,681 granted from it |
| Sep 20, 2018 | 2018/0264022 | A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. · patent 10,780,106 granted from it |
| Sep 15, 2016 | 2016/0263142 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. · patent 10,265,337 granted from it |
| Aug 6, 2015 | 2015/0216889 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Pharmaceuticals | CAN-FITE BIOPHARMA LTD. · patent 9,549,943 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.